SOURCE: Peak Pharmaceuticals, Inc.

Peak Pharmaceuticals, Inc.

March 26, 2015 09:00 ET

Canna-Pet® Receives Trademark Registration and Launches Dog Biscuits on Amazon Ahead of Schedule

BOULDER, CO--(Marketwired - Mar 26, 2015) -  Peak Pharmaceuticals, Inc. (OTCQB: PKPH) (the "Company"), and Canna-Pet®, a leading innovator of non-prescription cannabinoid products for animals, announced today they have been advised that the US Patent and Trademark Office has registered the Canna-Pet® trademark.

Peak Pharmaceuticals, as the exclusive license holder of the Canna-Pet® brand and products, is delighted by the news, which marks another milestone of the Company's strategic plan for the marketing of this increasingly popular, sector-leading product lineup. Peak Pharma will continue its focus on building Canna-Pet® into a nationally recognized brand and trusted leader in the pet supplement industry. 

In addition, the Company is very pleased to announce that its Canna-Biscuit lineup has launched ahead of schedule on Amazon. The three top selling flavors of this popular CBD-infused dog treat are now available, including Maple Bacon, Pumpkin Pie, and Turkey Cranberry.

In related news, Canna-Pet® users may wish to inquire with their pet insurer to ascertain if coverage is applicable when the product is purchased at the recommendation of a veterinarian. Cases of reimbursement through Trupanion and Petplan policies have been reported to the Company who further advises it is not affiliated with any insurance provider at this time.

Company CEO, Dr. Soren Mogelsvang notes, "We enjoy sharing good news, and the announcements this week add significant momentum to the recognition and growth of our brand. Trademark registration will add to our ability to protect the Canna-Pet® brand, and will help to strengthen our planned marketing initiatives. Our presence on Amazon and distribution by a growing number of veterinarians, combined with the possibility of pet insurance reimbursement, are propelling our goal of mainstream integration into the massive pet supply industry. We are truly delighted by today's news and we appreciate the continued enthusiasm and support from our customers and stakeholders alike as we continue to move ahead within this rapidly growing industry segment."

About Peak Pharmaceuticals, Inc. (OTCQB: PKPH)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based supplement products for the human and animal health markets. The company aims to become a global leader in the research, development, sales and marketing of hemp and cannabinoid based supplements. For more information visit www.peakpharma.com and follow us on Facebook and LinkedIn.

About Canna-Pet® Products for Pet Health
Canna-Pet offers non-prescription CBD products for domesticated animals such as cats and dogs. Canna-Pet® is the culmination of years of research and development to provide the benefits of hemp-based CBD and cannabinoids without the "high" typically associated with psychoactive components. The company uses non-GMO hemp as starting material and manufactures its products in the USA. Canna-Pet products differ from competing CBD products by offering a proprietary mix of multiple hemp derived cannabinoids and terpenes, not just CBD. Canna-Pet is a leading producer of safe, hemp-based, CBD containing products, which are available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc. (OTCQB: PKPH). Order online at: www.canna-pet.com or under "Pet Supplies" on Amazon, and join us on Facebook and Twitter.

Additional details of Peak Pharmaceuticals business, finances, appointments, risks and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov. For more information please visit www.peakpharma.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the U.S. Food and Drug Administration (USFDA). The products mentioned herein are not intended for human consumption, or to diagnose, treat, cure, or prevent any disease. Information contained or made available through the Canna-Pet® website or affiliate sites is not intended to constitute or substitute for legal or veterinary advice.

Contact Information